Chevy Chase, MD—The Endocrine Society today issued a Clinical Practice Guideline (CPG) for the diagnosis and treatment of polycystic ovary syndrome, the most common hormone disorder in women of reproductive age and a leading cause of infertility.
The CPG, entitled "Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline" will appear in the December 2013 issue of the Journal of Clinical Endocrinology and Metabolism (JCEM), a publication of The Endocrine Society.
Polycystic ovary syndrome, or PCOS, affects about 5 million women in the United States, according to the National Institutes of Health. The condition causes diverse symptoms, and its causes are poorly understood. The definition and even the name of PCOS have been subject to debate. An NIH panel concluded in January 2013 that the name's focus on a specific symptom – ovarian cysts - that is not present in all PCOS cases caused confusion about the condition. Three separate diagnostic classification systems have been developed to help identify PCOS.
"The Endocrine Society's CPG is designed to help physicians and patients navigate our evolving understanding of this complex condition," said Richard S. Legro, MD, of the Penn State University College of Medicine, and chair of the task force that authored the guideline. "The Society's recommendations allow physicians to make the diagnosis if clear symptoms are present without resorting to universal hormone tests or ultrasound screening."
In the CPG, The Endocrine Society recommends that a diagnosis be made if adult women have two of the three cardinal features of PCOS (diagnostic criteria supported by the NIH panel):
Other recommendations from the CPG include:
The Hormone Health Network, The Endocrine Society's public education arm, has published a fact sheet that explains how PCOS affects the body and outlines treatment options at http://www.hormone.org/diseases-and-conditions/womens-health/polycystic-ovary-syndrome.
Other members of The Endocrine Society task force that developed this CPG include: Silva A. Arslanian of Children's Hospital of Pittsburgh; David A. Ehrmann of University of Chicago; Kathleen M. Hoeger of University of Rochester Medical Center in Rochester, NY; M. Hassan Murad of The Mayo Clinic in Rochester, MN; Renato Pasquali of Orsola-Malpighi Hospital in Bologna, Italy; and Corrine K. Welt of Massachusetts General Hospital in Boston, MA.
The Society established the CPG Program to provide endocrinologists and other clinicians with evidence-based recommendations in the diagnosis and treatment of endocrine-related conditions. Each CPG is created by a task force of topic-related experts in the field. Task forces rely on scientific reviews of the literature in the development of CPG recommendations. The Endocrine Society does not solicit or accept corporate support for its CPGs. All CPGs are supported entirely by Society funds.
Founded in 1916, The Endocrine Society is the world's oldest, largest and most active organization devoted to research on hormones and the clinical practice of endocrinology. Today, The Endocrine Society's membership consists of over 16,000 scientists, physicians, educators, nurses and students in more than 100 countries. Society members represent all basic, applied and clinical interests in endocrinology. The Endocrine Society is based in Chevy Chase, Maryland. To learn more about the Society and the field of endocrinology, visit our site at http://www.endocrine.org. Follow us on Twitter at https://twitter.com/#!/EndoMedia.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.